4.4 Article

Histopathologic patterns among achalasia subtypes

Journal

NEUROGASTROENTEROLOGY AND MOTILITY
Volume 28, Issue 1, Pages 139-145

Publisher

WILEY
DOI: 10.1111/nmo.12711

Keywords

achalasia; esophagus; histopathology; immunohistochemistry; motility

Funding

  1. Public Health Service [DK07659, DK092217, DK056033]

Ask authors/readers for more resources

BackgroundAchalasia has three distinct manometric phenotypes. This study aimed to determine if there were corresponding histopathologic patterns. MethodsWe retrospectively examined surgical muscularis propria biopsies obtained from 46 patients during laparoscopic esophagomyotomy. Pre-operative (conventional) manometry tracings were reviewed by two expert gastroenterologists who categorized patients into Chicago Classification subtypes. Pathology specimens were graded on degree of neuronal loss, inflammation, fibrosis, and muscle changes. Key ResultsManometry studies were categorized as follows: type I (n = 20), type II (n = 20), type III (n = 3), and esophagogastric junction outflow obstruction (EGJOO) (n = 3). On histopathology, complete ganglion cell loss occurred in 74% of specimens, inflammation in 17%, fibrosis in 11%, and muscle atrophy in 2%. Comparing type I and type II specimens, there was a statistically significant greater proportion of type I specimens with aganglionosis (19/20 vs 13/20, p = 0.044) and a statistically significant greater degree of ganglion cell loss in type I specimens (Wilcoxon Rank-Sum, p = 0.016). CD3(+)/CD8(+) cytotoxic T cells represented the predominant inflammatory infiltrate on immunohistochemistry. Three patients had completely normal appearing tissue (1 each in type II, type III, EGJOO). Conclusions & InferencesThe greater degree, but similar pattern, of ganglion cell loss observed in type I compared to type II achalasia specimens suggests that type I achalasia represents a progression from type II achalasia. The spectrum of histopathologic findings - from complete neuronal loss to lymphocytic inflammation to apparently normal histopathology - emphasizes that achalasia' represents a pathogenically heterogeneous patient group with the commonality being EGJ outflow obstruction.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pathology

Composite Epstein-Barr Virus-Associated B-Cell Lymphoproliferative Disorder and Tubular Adenoma in a Rectal Polyp

Amy A. Lo, Juehua Gao, M. Sambasivia Rao, Guang-Yu Yang

INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2016)

Article Endocrinology & Metabolism

HKDC1 Is a Novel Hexokinase Involved in Whole-Body Glucose Use

Anton E. Ludvik, Carolina M. Pusec, Medha Priyadarshini, Anthony R. Angueira, Cong Guo, Amy Lo, Korri S. Hershenhouse, Guang-Yu Yang, Xianzhong Ding, Timothy E. Reddy, William L. Lowe, Brian T. Layden

ENDOCRINOLOGY (2016)

Article Gastroenterology & Hepatology

Adverse events after surgery for nonmalignant colon polyps are common and associated with increased length of stay and costs

Rajesh N. Keswani, Ryan Law, Jody D. Ciolino, Amy A. Lo, Adam B. Gluskin, David J. Bentrem, Sri Komanduri, Jennifer A. Pacheco, David Grande, William K. Thompson

GASTROINTESTINAL ENDOSCOPY (2016)

Article Oncology

Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model

Danielle Mandikian, Nene Takahashi, Amy A. Lo, Ji Li, Jeffrey Eastham-Anderson, Dionysos Slaga, Jason Ho, Maria Hristopoulos, Robyn Clark, Klara Totpal, Kedan Lin, Sean B. Joseph, Mark S. Dennis, Saileta Prabhu, Teemu T. Junttila, C. Andrew Boswell

MOLECULAR CANCER THERAPEUTICS (2018)

Article Cell Biology

Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3

Dionysos Slaga, Diego Ellerman, T. Noelle Lombana, Rajesh Vij, Ji Li, Maria Hristopoulos, Robyn Clark, Jennifer Johnston, Amy Shelton, Elaine Mai, Kapil Gadkar, Amy A. Lo, James T. Koerber, Klara Totpal, Rodney Prell, Genee Lee, Christoph Spiess, Teemu T. Junttila

SCIENCE TRANSLATIONAL MEDICINE (2018)

Review Oncology

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Jan Hudecek, Leonie Voorwerk, Maartje van Seijen, Iris Nederlof, Michiel de Maaker, Jose van den Berg, Koen K. van de Vijver, Karolina Sikorska, Sylvia Adams, Sandra Demaria, Giuseppe Viale, Torsten O. Nielsen, Sunil S. Badve, Stefan Michiels, William Fraser Symmans, Christos Sotiriou, David L. Rimm, Stephen M. Hewitt, Carsten Denkert, Sibylle Loibl, Sherene Loi, John M. S. Bartlett, Giancarlo Pruneri, Deborah A. Dillon, Maggie C. U. Cheang, Andrew Tutt, Jacqueline A. Hall, Zuzana Kos, Roberto Salgado, Marleen Kok, Hugo M. Horlings

NPJ BREAST CANCER (2020)

Article Oncology

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Zuzana Kos, Elvire Roblin, Rim S. Kim, Stefan Michiels, Brandon D. Gallas, Weijie Chen, Koen K. van de Vijver, Shom Goel, Sylvia Adams, Sandra Demaria, Giuseppe Viale, Torsten O. Nielsen, Sunil S. Badve, W. Fraser Symmans, Christos Sotiriou, David L. Rimm, Stephen Hewitt, Carsten Denkert, Sibylle Loibl, Stephen J. Luen, John M. S. Bartlett, Peter Savas, Giancarlo Pruneri, Deborah A. Dillon, Maggie Chon U. Cheang, Andrew Tutt, Jacqueline A. Hall, Marleen Kok, Hugo M. Horlings, Anant Madabhushi, Jeroen van der Laak, Francesco Ciompi, Anne-Vibeke Laenkholm, Enrique Bellolio, Tina Gruosso, Stephen B. Fox, Juan Carlos Araya, Giuseppe Floris, Jan Hudecek, Leonie Voorwerk, Andrew H. Beck, Jen Kerner, Denis Larsimont, Sabine Declercq, Gert Van den Eynden, Lajos Pusztai, Anna Ehinger, Wentao Yang, Khalid AbdulJabbar, Yinyin Yuan, Rajendra Singh, Crispin Hiley, Maise al Bakir, Alexander J. Lazar, Stephen Naber, Stephan Wienert, Miluska Castillo, Giuseppe Curigliano, Maria-Vittoria Dieci, Fabrice Andre, Charles Swanton, Jorge Reis-Filho, Joseph Sparano, Eva Balslev, I-Chun Chen, Elisabeth Ida Specht Stovgaard, Katherine Pogue-Geile, Kim R. M. Blenman, Frederique Penault-Llorca, Stuart Schnitt, Sunil R. Lakhani, Anne Vincent-Salomon, Federico Rojo, Jeremy P. Braybrooke, Matthew G. Hanna, M. Teresa Soler-Monso, Daniel Bethmann, Carlos A. Castaneda, Karen Willard-Gallo, Ashish Sharma, Huang-Chun Lien, Susan Fineberg, Jeppe Thagaard, Laura Comerma, Paula Gonzalez-Ericsson, Edi Brogi, Sherene Loi, Joel Saltz, Frederick Klaushen, Lee Cooper, Mohamed Amgad, David A. Moore, Roberto Salgado

NPJ BREAST CANCER (2020)

Article Pathology

Innovative Tumor Tissue Dissection Tool for Molecular Oncology Diagnostics

Manana Javey, Christina Reinsch, Mirjam Feldkamp, Sandra Siemann, Anja Blueher, Corinna Woestmann, Lingling Cai, Ian Tran, Theresa May, Charles Havnar, Amy A. Lo, Bernd Hinzmann, Gabrielle Heilek, John F. Palma

Summary: This study compared the performance of an automated tissue dissection tool with manual dissection methods in FFPE tissue specimens, with the automated method resulting in significantly higher yields of nucleic acids and proteins. The downstream analysis showed highly concordant results for EGFR mutation testing and significantly higher allelic frequencies for next-generation sequencing when tissue was dissected by the automated method.

JOURNAL OF MOLECULAR DIAGNOSTICS (2021)

Article Oncology

Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer

Amy A. Lo, Jennifer Johnston, Ji Li, Danielle Mandikian, Maria Hristopoulos, Robyn Clark, Dorothee Nickles, Wei-Ching Liang, Kathy Hotzel, Debra Dunlap, Thinh Pham, Hao Cai, Meric Ovacik, Daniel Bravo-Perez, Elaine Mai, Dionysos Slaga, Diego Ellerman, James Ziai, Klara Totpal, Genee Lee, C. Andrew Boswell, Jian Payandeh, Yan Wu, Teemu T. Junttila

Summary: LYPD1 is a novel target for therapeutic antibodies for the treatment of ovarian cancer, showing broad expression in both primary and metastatic ovarian cancer, particularly in the serous cancer subset. The anti-LYPD1/CD3 T-cell-dependent bispecific antibody demonstrates significant clinical activity in inducing T-cell responses and killing LYPD1 expressing ovarian cancer cells with efficient anti-tumor responses in preclinical studies.

MOLECULAR CANCER THERAPEUTICS (2021)

Article Oncology

Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies

Amy A. Lo, Andrew Wallace, Daniel Oreper, Nicolas Lounsbury, Charles Havnar, Ximo Pechuan-Jorge, Thomas D. Wu, Richard Bourgon, Ryan Jones, Katrina Krogh, Guang-Yu Yang, Oliver A. Zill

Summary: The distribution of clonal neoantigens varies across different cancer types, and factors influencing neoantigen targeting include tumor type, multilesion sampling, neoantigen expression, and HLA allele retention. Prioritizing mutations with higher purity-adjusted and ploidy-adjusted variant allele frequency enriches for globally clonal neoantigens.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Article Oncology

Origins and Timing of Emerging Lesions in Advanced Renal Cell Carcinoma

Andrew Wallace, Sima P. Porten, Amy A. Lo, Daniel Oreper, Nicolas Lounsbury, Charles Havnar, Ximo Pechuan-Jorge, Oliver A. Zill, Maxwell V. Meng

Summary: This study analyzed the genomic alterations and molecular pathways associated with renal cell carcinoma (RCC) with venous tumor thrombus (VTT) and distant metastasis. The results showed that VTT did not have specific genomic alterations, while metastasis and disease recurrence were associated with certain copy-number alterations and secondary driver alterations. The study also found that metastasis generally occurred before VTT, with the earliest metastases predicted to emerge years before diagnosis. Furthermore, VTT upregulated immediate-early genes and transcriptional targets of the TNF alpha/NF-kappa B pathway, while metastases upregulated MTOR and transcriptional targets downstream of mTORC1 activation.

MOLECULAR CANCER RESEARCH (2022)

Article Oncology

Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer

Peiyin Wang, Liping L. Sun, Robyn Clark, Maria Hristopoulos, Cecilia P. C. Chiu, Michael Dillon, WeiYu Lin, Amy A. Lo, Sreedevi Chalsani, Meghna Das Thakur, Kristin M. Zimmerman Savill, Lionel Rouge, Patrick Lupardus, Robert Piskol, Bushra Husain, Diego Ellerman, Vittal Shivva, Steven R. Leong, Meric Ovacik, Klara Totpal, Yan Wu, Christoph Spiess, Genee Lee, Douglas D. Leipold, Andrew G. Polson

Summary: New discoveries in the treatment of colorectal cancer have shown significant clinical improvements, but certain subsets of patients still do not benefit from current immune modulators. This article describes the development of a novel T-cell-dependent bispecific antibody (TDB) that targets colorectal cancer. The antibody demonstrates potent antitumor activity and enhanced efficacy when combined with PD-1 blockade. These findings provide evidence for the therapeutic potential of LY6G6D-TDB in colorectal cancer.

MOLECULAR CANCER THERAPEUTICS (2022)

Article Oncology

Complete and Prolonged Response to Immune Checkpoint Blockade in POLE-Mutated Colorectal Cancer

Robyn Silberman, David F. Steiner, Amy A. Lo, Adam Gomez, James L. Zehnder, Gilbert Chu, Carlos J. Suarez

JCO PRECISION ONCOLOGY (2019)

Review Pathology

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research

Shona Hendry, Roberto Salgado, Thomas Gevaert, Prudence A. Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen van de Vijver, M. V Estrada, Paula I Gonzalez-Ericsson, Melinda Sanders, Benjamin sss Solomon, Cinzia Solinas, Gert G. G. M. Van den Eynden, Yves Allory, Matthias Preusser, Johannes Hainfellner, Giancarlo Pruneri, Andrea Vingiani, Sandra Demaria, Fraser Symmans, Paolo Nuciforo, Laura Comerma, E. A. Thompson, Sunil Lakhani, Seong-Rim Kim, Stuart Schnitt, Cecile Colpaert, Christos Sotiriou, Stefan J. Scherer, Michail Ignatiadis, Sunil Badve, Robert H. Pierce, Giuseppe Viale, Nicolas Sirtaine, Frederique Penault-Llorca, Tomohagu Sugie, Susan Fineberg, Soonmyung Paik, Ashok Srinivasan, Andrea Richardson, Yihong Wang, Ewa Chmielik, Jane Brock, Douglas B. Johnson, Justin Balko, Stephan Wienert, Veerle Bossuyt, Stefan Michiels, Nils Ternes, Nicole Burchardi, Stephen J. Luen, Peter Savas, Frederick Klauschen, Peter H. Watson, Brad H. Nelson, Carmen Criscitiello, Sandra O'Toole, Denis Larsimont, Roland de Wind, Giuseppe Curigliano, Fabrice Andre, Magali Lacroix-Triki, Mark van de Vijver, Federico Rojo, Giuseppe Floris, Shahinaz Bedri, Joseph Sparano, David Rimm, Torsten Nielsen, Zuzana Kos, Stephen Hewitt, Baljit Singh, Gelareh Farshid, Sibylle Loibl, Kimberly H. Allison, Nadine Tung, Sylvia Adams, Karen Willard-Gallo, Hugo M. Horlings, Leena Gandhi, Andre Moreira, Fred Hirsch, Maria V. Dieci, Maria Urbanowicz, Iva Brcic, Konstanty Korski, Fabien Gaire, Hartmut Koeppen, Amy Lo, Jennifer Giltnane, Marlon C. Rebelatto, Keith E. Steele, Jiping Zha, Kenneth Emancipator, Jonathan W. Juco, Carsten Denkert, Jorge Reis-Filho, Sherene Loi, Stephen B. Fox

ADVANCES IN ANATOMIC PATHOLOGY (2017)

No Data Available